There’s a reason that venture firms in Boston love building their own companies: It helps to have a hand-picked leader with a proven track record at the helm of an early-stage biotech company.

Waltham, Mass.-based Skyhawk Therapeutics is bucking that trend with gusto. In June 2018, the company announced a $100 million early-stage venture fundraising round and partnership deals with Biogen and Celgene (which was just acquired by Bristol-Myers Squibb for $74 billion). Earlier this month, the company was at the annual J.P. Morgan Healthcare Conference looking for more. Yet their chief executive officer, Bill Haney, has less than five years of experience as a biotech executive; his only other biotech company is Dragonfly Therapeutics.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Well, it seems like you will never be as good at convincing investors of anything, but rather sound like a complete tool who thinks he is owed something. And as to your credentials, you can shove them. Credentials don’t equal creativity… tool.

  • Fun fact:
    neither the CEO/co-founder, nor the CSO/co-founder have either an MD and/or a PhD degree. They must be so good they didn’t need one. Even more so, by claiming they are creating innovative treatments.

    I wish I was as good as them at convincing investors despite not having adequate scientific credentials. Maybe, that’s the problem, I actually have proper scientific credentials.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy